Update on systemic therapy of advanced non-small-cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Significant progress in advanced non-small-cell lung cancer (NSCLC) treatment has occurred in the last decade.
• This progress is driven by a deeper understanding of lung cancer's molecular biology and the identification of new oncogene drivers.

Purpose of the Study:

• To review major developments in both oncogene-directed and non-oncogene-directed therapies for advanced NSCLC.
• To discuss future treatment strategies, including immunotherapy.

Main Methods:

• Review of current literature on lung cancer molecular biology and targeted therapies.
• Analysis of clinical outcomes for EGFR and ALK tyrosine kinase inhibitors.
• Evaluation of chemotherapy advancements based on tumor histology and response.
• Identification of emerging treatment strategies.

Main Results:

• Oncogene-directed therapies (EGFR, ALK inhibitors) are standard for specific mutations, improving median survival to up to 35 months.
• Tailored chemotherapy based on histology and response raises median survival to 13 months.
• Numerous targeted drugs and strategies are under development.

Conclusions:

• Targeted therapies and tailored chemotherapy have substantially improved outcomes in advanced NSCLC.
• Immunotherapy represents a promising future strategy for NSCLC treatment.
• Continued research into molecular drivers and novel therapeutic approaches is crucial for further advancements.